An Open Label, Single-center, Phase 1 Study to Evaluate the Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cell in Patients With Chronic Kidney Disease
Latest Information Update: 26 Mar 2024
At a glance
- Drugs Cellgram-CKD (Primary)
- Indications Renal failure
- Focus Adverse reactions
- Sponsors Pharmicell
Most Recent Events
- 21 Mar 2024 Status changed from recruiting to completed.
- 13 Oct 2021 Planned initiation date changed from 1 Sep 2021 to 1 Oct 2021.
- 13 Oct 2021 Status changed from not yet recruiting to recruiting.